TickerSpark Feed

MEDP coverage

Every article, report, and earnings note where MEDP appears.

Clinical Research and Pharma Services Stocks That Reward Quality: 3 Picks

Three clinical research and pharma services stocks ranked by investment quality, weighing scale, execution, profitability, growth, and valuation.

Aug 15, 2026·8 MIN

clinical research and pharma services

Trending StockMEDP

Medpace Holdings, Inc. (MEDP) falls 14.5% after hours

Medpace Holdings, Inc. (MEDP) falls sharply in after-hours trading after a strong post-earnings run. The move looks driven more by profit-taking and valuation pressure than by a new company-specific setback, even as the CRO’s backlog, bookings, and raised guidance remain solid.

Jul 29, 2026·6 MIN

Trending StockMEDP

Medpace Holdings, Inc. (MEDP) jumps 18% on Q2 beat

Medpace Holdings, Inc. (MEDP) jumps after-hours after posting a strong Q2 2026 earnings beat, higher revenue, and improved bookings. The CRO also raised full-year revenue guidance, signaling healthy demand and reinforcing its premium growth profile.

Jul 23, 2026·5 MIN

Research ReportMEDP

Medpace Holdings (MEDP): Growth Quality vs. Booking Risk

Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.

Jul 22, 2026·21 MIN

Healthcare Diagnostics & Research Healthcare

Trending StockMEDP

Medpace Holdings, Inc. (MEDP) slumps 17% on bookings miss

Medpace Holdings, Inc. (MEDP) slumps after hours despite a strong first quarter, as investors focus on weaker bookings and a sub-1.0x book-to-bill ratio. The company beat on revenue and earnings, but concerns about future demand and backlog growth drove the sharp selloff.

Apr 23, 2026·6 MIN

Trending StockMEDP

Medpace Holdings, Inc. (MEDP) Slumps After Q1 Beat

Medpace Holdings, Inc. (MEDP) slumps nearly 19% after hours after a Q1 earnings beat failed to impress investors. Strong revenue and EPS were overshadowed by softer bookings and guidance that did not raise expectations enough for a premium-valued CRO.